Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the Pharmalot campus has quieted down. The shortest person has left for a new summer job overseeing even smaller people and the official mascots are enjoying snoozes under windows where cool breezes and a warm sunshine can be felt. As for us, we are quaffing cups of stimulation that sport a hint of Jack Daniel’s. As always, feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits. Hope you have a smashing day and please do keep in touch …
The House is touting passage of dozens of bills that could help combat the national opioid crisis, but a small handful of companies that have spent millions lobbying Congress could reap a windfall if any of the bills become law, Politico informs us. Among them is Alkermes (ALKS), which spent $1 million lobbying in part to support a bill to fund full-service centers where people can detox, receive medical care, and start treatment — a setup that could boost the fortunes of its best-selling product, anti-addiction treatment Vivitrol.
About the Author Reprints
